Cancel
Known information
- Served as the founding CEO and a Director of Alnylam Pharmaceuticals from 2002 to 2021
- Built and led Alnylam Pharmaceuticals from early platform research on RNA interference through global approval and commercialization of the first four RNAi therapeutic medicines
- Led Alnylam Pharmaceuticals’ value creation strategy, building over $25 billion in market capitalization and forming over 20 major pharmaceutical alliances
- Continues to serve on the Alnylam Scientific Advisory Board
- Worked at Millennium Pharmaceuticals, Inc., responsible for product franchises in oncology, cardiovascular, inflammatory, and metabolic diseases
- Held scientific and business roles at Biogen, Inc., where he invented and led the discovery and development of ANGIOMAX® (bivalirudin) for injection
- Previously a scientist at ZymoGenetics, Inc. and the Upjohn Company
- Currently a Venture Partner at ARCH Venture Partners
- Chairman and Co-founder of Orbital Therapeutics
- Venture Advisor at Atlas Ventures
- Executive Partner at RTW Investments
- Senior Advisor for Blackstone Life Sciences
- Member of the Board of Directors of publicly traded companies including Agios Pharmaceuticals, Beam Therapeutics, Kymera Therapeutics, ProKidney Corp., and Takeda Pharmaceuticals
- On the Board of a number of private companies including Aerium, Hemab, Aera, and Versanis
- On the Board of the Biotechnology Innovation Organization (BIO), where he was Chair from 2017-2019 and is Chair Emeritus
- Serves on the Board of the Termeer Foundation
- Chair of the n-Lorem Foundation Advisory Council
- On the Advisory Board of Ariadne Labs
- Advisor to Nucleate
- Received his M.S. and Ph.D. in biochemistry and molecular biology at the University of Chicago
About Aera Therapeutics
Aera Therapeutics, headquartered in Cambridge, MA, focuses on advancing genetic medicines using a proprietary protein nanoparticle delivery platform and a therapeutic enzyme platform for gene editing.
Report inaccurate information
